These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16515872)

  • 21. Imiglucerase treatment in Gaucher's disease.
    Shah U; Nadeem N; Husen Y; Fadoo Z
    J Ayub Med Coll Abbottabad; 2007; 19(2):56-9. PubMed ID: 18183722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming the Next Barriers to Successful Therapy.
    Cohen IJ; Baris H; Mistry PK; Sands MS
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209
    [No Abstract]   [Full Text] [Related]  

  • 23. The cost of treating Gaucher disease.
    Beutler E
    Nat Med; 1996 May; 2(5):523-4. PubMed ID: 8616707
    [No Abstract]   [Full Text] [Related]  

  • 24. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
    Butters TD; Dwek RA; Platt FM
    Adv Exp Med Biol; 2003; 535():219-26. PubMed ID: 14714898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.
    Shachar T; Lo Bianco C; Recchia A; Wiessner C; Raas-Rothschild A; Futerman AH
    Mov Disord; 2011 Aug; 26(9):1593-604. PubMed ID: 21618611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gaucher disease and its treatment options.
    Bennett LL; Mohan D
    Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective.
    Shayman JA
    Am J Physiol Renal Physiol; 2015 Dec; 309(12):F996-9. PubMed ID: 26447223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.
    MacKenzie JJ; Amato D; Clarke JT
    CMAJ; 1998 Nov; 159(10):1273-8. PubMed ID: 9861225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Why Genzyme can charge so much for Cerezyme.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A15. PubMed ID: 16502533
    [No Abstract]   [Full Text] [Related]  

  • 31. Enzyme replacement therapy for Gaucher Disease: the only experience in Malaysia.
    Chan LL; Lin HP
    Med J Malaysia; 2002 Sep; 57(3):348-52. PubMed ID: 12440275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Gaucher disease type 1--therapeutic results of enzyme substitution].
    Steensberg J; Nielsen KG; Brandt NJ
    Ugeskr Laeger; 1998 Jun; 160(26):3929-30. PubMed ID: 9656836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Enzyme replacement therapy of patients with lysosomal storage disease].
    Takada G; Takahashi T
    Nihon Rinsho; 1995 Dec; 53(12):3077-82. PubMed ID: 8577062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lysosomal storage disorders. Preface.
    Hollak CE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):125-6. PubMed ID: 25987167
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacologic chaperoning as a strategy to treat Gaucher disease.
    Yu Z; Sawkar AR; Kelly JW
    FEBS J; 2007 Oct; 274(19):4944-50. PubMed ID: 17894779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uncertain miracle: a biotech drug extends a life, but at what price? For Ms. Lees, treatment bill now totals $7 million; her bones keep crumbling; guilt of another $1,400 day.
    Wall St J (East Ed); 2005 Nov; ():A1, A15. PubMed ID: 16502532
    [No Abstract]   [Full Text] [Related]  

  • 37. Stop-codon read-through for patients affected by a lysosomal storage disorder.
    Brooks DA; Muller VJ; Hopwood JJ
    Trends Mol Med; 2006 Aug; 12(8):367-73. PubMed ID: 16798086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease?
    Trapero A; Llebaria A
    Future Med Chem; 2014 Jun; 6(9):975-8. PubMed ID: 25068980
    [No Abstract]   [Full Text] [Related]  

  • 39. [Enzyme substitution in Gauscher disease].
    Steensberg J; Nielsen KG; Brandt NJ
    Ugeskr Laeger; 1998 Jun; 160(26):3900-3. PubMed ID: 9656829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.